<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Vaccine Candidates Currently Being Developed</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Category</th>
    <th>Sponsor/ company</th>
    <th>Strategy</th>
    <th>Phase</th>
    <th>Mechanism and potency assay</th>
    <th>Reference</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="3">HA protein-based vaccine</td>
    <td>Novavax, Inc.</td>
    <td>HA Rosettes, HA nanoparticles, VLP with Matrix-MTM adjuvant</td>
    <td>I/II</td>
    <td>Particle format for potency, multiple strains mixed or sequential delivery; HAI and MN assay</td>
    <td>[
     <xref ref-type="bibr" rid="CR45">45</xref>–
     <xref ref-type="bibr" rid="CR47">47</xref>]
    </td>
   </tr>
   <tr>
    <td>NIH, GSK, and Icahn School of Medicine at Mount Sinai</td>
    <td>HA stem or head-stem chimera</td>
    <td>I</td>
    <td>bnAbs (no HAI) and ADCC; intranasal influenza challenge</td>
    <td>[
     <xref ref-type="bibr" rid="CR48">48</xref>–
     <xref ref-type="bibr" rid="CR51">51</xref>]
    </td>
   </tr>
   <tr>
    <td>Academia Sinica and OPKO</td>
    <td>Monoglycosylated HA as universal flu vaccine, exposing the conserved domain to elicit bnAbs</td>
    <td>preclinical</td>
    <td>Broad cross-reactive Ab; HAI and MN assay</td>
    <td>[
     <xref ref-type="bibr" rid="CR52">52</xref>–
     <xref ref-type="bibr" rid="CR54">54</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="2">Epitope-peptides based vaccine</td>
    <td>BiondVax Pharmaceuticals Ltd</td>
    <td>HA, NP, M1 peptides</td>
    <td>II/III</td>
    <td>Cytotoxic T lymphocytes (CTL) response</td>
    <td>[
     <xref ref-type="bibr" rid="CR55">55</xref>–
     <xref ref-type="bibr" rid="CR58">58</xref>]
    </td>
   </tr>
   <tr>
    <td>PepTcell.Ltd</td>
    <td>FLU-V</td>
    <td>II</td>
    <td>Cross-reactive T-cell responses, and mucosal immunity; intranasal influenza challenge</td>
    <td>[
     <xref ref-type="bibr" rid="CR59">59</xref>–
     <xref ref-type="bibr" rid="CR63">63</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="2">Live attenuated virus vaccine</td>
    <td>CodageniX</td>
    <td>CodaVax Live-attenuated and single-round whole virus</td>
    <td>I/II</td>
    <td>Additional antigens, T cell responses, and mucosal immunity; intranasal influenza challenge</td>
    <td>[
     <xref ref-type="bibr" rid="CR64">64</xref>–
     <xref ref-type="bibr" rid="CR66">66</xref>]
    </td>
   </tr>
   <tr>
    <td>FluGen</td>
    <td>M2SR</td>
    <td>I/II</td>
    <td>T cell responses, and mucosal immunity; intranasal influenza challenge</td>
    <td>[
     <xref ref-type="bibr" rid="CR67">67</xref>, 
     <xref ref-type="bibr" rid="CR68">68</xref>]
    </td>
   </tr>
   <tr>
    <td>DNA based vaccine</td>
    <td>Inovio</td>
    <td>RNA, DNA, or vector subunit delivery</td>
    <td>I</td>
    <td>Gene delivery for CTL and Ab</td>
    <td>[
     <xref ref-type="bibr" rid="CR69">69</xref>–
     <xref ref-type="bibr" rid="CR72">72</xref>]
    </td>
   </tr>
   <tr>
    <td>M2-based protein vaccine</td>
    <td>Acambis/Sanofi Pasteur</td>
    <td>M2 ectodomain</td>
    <td>I/II</td>
    <td>bnAbs; ADCC (no NT); intranasal influenza challenge</td>
    <td>[
     <xref ref-type="bibr" rid="CR73">73</xref>, 
     <xref ref-type="bibr" rid="CR74">74</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
